Literature DB >> 18991646

Genetic modifiers in hemoglobinopathies.

Deborah Rund1, Suthat Fucharoen.   

Abstract

Hereditary anemias show considerable variation in their clinical presentation. In some cases, the causes of these variations are easily apparent. In thalassemia (or in HbE/thalassemia), genetic variation is primarily caused by the severity of the thalassemia mutation. However, not uncommonly, there is variation unexplained by the globin gene mutations themselves, which may be caused by genetic modifiers. In sickle cell disease, the primary mutation is the same in all patients. Therefore, variations in disease severity generally are due to genetic modifiers. In most genetic diseases involving beta globin, the most clearcut influence on phenotype results from elevated fetal hemoglobin levels. In addition, alpha globin gene number can influence disease phenotype. In thalassemia major or intermedia, reduction in the number of alpha globin genes can ameliorate the disease phenotype; conversely, excess alpha globin genes can convert beta thalassemia trait to a clinical picture of thalassemia intermedia. In sickle cell disease, the number of alpha globin genes has both ameliorating and exacerbating effects, depending on which disease manifestation is being examined. Unlinked genetic factors have substantial effects on the phenotype of hereditary anemias, both on the anemia and other disease manifestations. Recently, studies using genome-wide techniques, particularly studying QTLs causing elevated HbF, or affecting HbE/thalassemia, have revealed other genetic elements whose mechanisms are under study. The elucidation of genetic modifiers will hopefully lead to more rational and effective management of these diseases.

Entities:  

Mesh:

Year:  2008        PMID: 18991646     DOI: 10.2174/156652408786241410

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  8 in total

1.  MALDI-TOF MS in Prenatal Genomics.

Authors:  Xiao Yan Zhong; Wolfgang Holzgreve
Journal:  Transfus Med Hemother       Date:  2009-06-25       Impact factor: 3.747

2.  Phenotypic effect of α-globin gene numbers on Indian sickle β-thalassemia patients.

Authors:  Sanjay Kumar Pandey; Sweta Pandey; Ravi Ranjan; Vineet Shah; Rahasya Mani Mishra; Monica Sharma; Renu Saxena
Journal:  J Clin Lab Anal       Date:  2014-01-06       Impact factor: 2.352

3.  Interaction of malaria with a common form of severe thalassemia in an Asian population.

Authors:  A O'Donnell; A Premawardhena; M Arambepola; R Samaranayake; S J Allen; T E A Peto; C A Fisher; J Cook; P H Corran; Nancy F Olivieri; D J Weatherall
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

4.  β-Globin chain abnormalities with coexisting α-thalassemia mutations.

Authors:  Birol Guvenc; Abdullah Canataroglu; Cagatay Unsal; Sule Menziletoglu Yildiz; Ferda Tekin Turhan; Sevcan Tug Bozdogan; Suleyman Dincer; Hakan Erkman
Journal:  Arch Med Sci       Date:  2012-05-29       Impact factor: 3.318

Review 5.  Abnormal haemoglobins: detection & characterization.

Authors:  Henri Wajcman; Kamran Moradkhani
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

6.  Molecular analysis of beta-globin gene mutations among Thai beta-thalassemia children: results from a single center study.

Authors:  Boonchai Boonyawat; Chalinee Monsereenusorn; Chanchai Traivaree
Journal:  Appl Clin Genet       Date:  2014-12-10

7.  Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.

Authors:  Olivier Negre; Anne-Virginie Eggimann; Yves Beuzard; Jean-Antoine Ribeil; Philippe Bourget; Suparerk Borwornpinyo; Suradej Hongeng; Salima Hacein-Bey; Marina Cavazzana; Philippe Leboulch; Emmanuel Payen
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

8.  Editorial: Genetics and Genomics of Red Blood Cells.

Authors:  Achille Iolascon; Roberta Russo; Immacolata Andolfo
Journal:  Front Physiol       Date:  2022-01-07       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.